Sucampo Pharmaceuticals (SCMP) Price Target Increased to $18.00 by Analysts at B. Riley

Sucampo Pharmaceuticals (NASDAQ:SCMP) had its price objective hoisted by B. Riley from $14.00 to $18.00 in a research report sent to investors on Wednesday morning. They currently have a buy rating on the biopharmaceutical company’s stock.

Other analysts also recently issued reports about the company. Maxim Group reissued a buy rating and issued a $23.00 target price on shares of Sucampo Pharmaceuticals in a report on Thursday, November 2nd. Mizuho cut Sucampo Pharmaceuticals from a buy rating to a neutral rating and dropped their price target for the company from $14.00 to $12.00 in a research report on Tuesday, October 3rd. BidaskClub upgraded Sucampo Pharmaceuticals from a hold rating to a buy rating in a research report on Tuesday. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, October 3rd. Finally, Leerink Swann began coverage on Sucampo Pharmaceuticals in a research report on Monday, August 21st. They issued an outperform rating and a $15.00 price target on the stock. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Sucampo Pharmaceuticals currently has a consensus rating of Buy and an average price target of $16.40.

Sucampo Pharmaceuticals (SCMP) traded up $0.75 during trading on Wednesday, hitting $14.95. The stock had a trading volume of 5,461,100 shares, compared to its average volume of 725,432. Sucampo Pharmaceuticals has a fifty-two week low of $9.30 and a fifty-two week high of $17.24. The company has a debt-to-equity ratio of 7.37, a current ratio of 5.11 and a quick ratio of 4.46. The stock has a market cap of $728.70, a P/E ratio of 9.73, a P/E/G ratio of 4.23 and a beta of 1.47.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.25 by $0.02. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The business had revenue of $61.27 million during the quarter, compared to the consensus estimate of $58.05 million. During the same period in the previous year, the business earned $0.30 EPS. The business’s quarterly revenue was up 5.9% on a year-over-year basis. sell-side analysts forecast that Sucampo Pharmaceuticals will post 1.12 earnings per share for the current year.

In other Sucampo Pharmaceuticals news, major shareholder Sachiko Kuno sold 1,000,000 shares of the business’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $12.00, for a total transaction of $12,000,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 4.13% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. HPM Partners LLC purchased a new stake in shares of Sucampo Pharmaceuticals during the 2nd quarter worth approximately $1,307,000. Louisiana State Employees Retirement System boosted its stake in shares of Sucampo Pharmaceuticals by 1.0% during the 2nd quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 100 shares in the last quarter. Trexquant Investment LP purchased a new stake in shares of Sucampo Pharmaceuticals during the 3rd quarter worth approximately $122,000. Nine Chapters Capital Management LLC purchased a new stake in shares of Sucampo Pharmaceuticals during the 3rd quarter worth approximately $127,000. Finally, JPMorgan Chase & Co. purchased a new stake in shares of Sucampo Pharmaceuticals during the 2nd quarter worth approximately $117,000. Institutional investors own 65.31% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.chaffeybreeze.com/2017/12/07/sucampo-pharmaceuticals-scmp-price-target-increased-to-18-00-by-analysts-at-b-riley.html.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply